HeartBeam's 3D ECG Matches Standard 12-Lead in Heart Attack Pilot, Pivotal Study Set for Q1 2027
BEAT sits 52% above its 52-week low of $0.355 on light trading volume (0.2× avg).
Summary
HeartBeam's ALIGN-ACS pilot met its goal: in 132 patients at two Belgrade emergency departments, patient-recorded 3D ECGs read by blinded cardiologists were broadly comparable to standard 12-lead ECGs. Specificity was higher (81.8% vs 71.4%) and sensitivity slightly lower (60.2% vs 63.0%); for STEMI, the most time-critical category, sensitivity was essentially equal (82.9% vs 83.8%). All 132 patients captured their own recording with no prior training, and inter-reader agreement was better than with 12-lead (kappa 0.73 vs 0.54). This is the readout the company flagged when it announced enrollment completion on September 28, and it follows the October 5 FDA Breakthrough Device Designation and the October 26 TAP pilot acceptance. The heart attack indication is still investigational and not FDA cleared, so no revenue follows from this — the value is in de-risking the path to a U.S. pivotal study starting Q1 2027. Cash is the constraint: $8.7 million on hand at Q2 with a going concern warning and a $25 million ATM in place, so dilution risk remains live while that trial is funded. Watch the Q1 2027 pivotal study start and any FDA feedback on the design.
At the time of this announcement, BEAT was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31M. The 52-week trading range was $0.36 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.